Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells

Standard

Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells. / Romanenko, Margarita V.; Dolgova, Evgeniya V.; Osipov, Ivan D. et al.

In: Anticancer research, Vol. 39, No. 11, 01.11.2019, p. 6073-6086.

Research output: Contribution to journal › Article › peer-review

Harvard

Romanenko, MV, Dolgova, EV, Osipov, ID, Ritter, GS, Sizova, MS, Proskurina, AS, Efremov, YR, Bayborodin, SI, Potter, EA, Taranov, OS, Omigov, VV, Kochneva, GV, Grazhdantseva, AA, Zavyalov, EL, Razumov, IA, Netesov, SV & Bogachev, SS 2019, 'Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells', Anticancer research, vol. 39, no. 11, pp. 6073-6086. https://doi.org/10.21873/anticanres.13815

APA

Romanenko, M. V., Dolgova, E. V., Osipov, I. D., Ritter, G. S., Sizova, M. S., Proskurina, A. S., Efremov, Y. R., Bayborodin, S. I., Potter, E. A., Taranov, O. S., Omigov, V. V., Kochneva, G. V., Grazhdantseva, A. A., Zavyalov, E. L., Razumov, I. A., Netesov, S. V., & Bogachev, S. S. (2019). Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells. Anticancer research, 39(11), 6073-6086. https://doi.org/10.21873/anticanres.13815

Vancouver

Romanenko MV, Dolgova EV, Osipov ID, Ritter GS, Sizova MS, Proskurina AS et al. Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells. Anticancer research. 2019 Nov 1;39(11):6073-6086. doi: 10.21873/anticanres.13815

Author

Romanenko, Margarita V. ; Dolgova, Evgeniya V. ; Osipov, Ivan D. et al. / Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells. In: Anticancer research. 2019 ; Vol. 39, No. 11. pp. 6073-6086.

BibTeX

@article{85c35b64062941e2a9bbfdd55faf0779,

title = "Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells",

abstract = "BACKGROUND/AIM: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. MATERIALS AND METHODS: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. RESULTS: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. CONCLUSION: Ad6 was shown to be a promising agent for treating glioblastomas.",

keywords = "Adenovirus, cancer stem cells, DNA internalization, TAMRA, U87 cell line, Cell Proliferation, Humans, Neoplastic Stem Cells/metabolism, Adenoviruses, Human/classification, Mice, SCID, Glioblastoma/genetics, Oncolytic Virotherapy, Xenograft Model Antitumor Assays, Animals, Virus Replication, Mice, Tumor Cells, Cultured, Apoptosis, Cancer stem cells, Аdenovirus",

author = "Romanenko, {Margarita V.} and Dolgova, {Evgeniya V.} and Osipov, {Ivan D.} and Ritter, {Genrikh S.} and Sizova, {Mariya S.} and Proskurina, {Anastasia S.} and Efremov, {Yaroslav R.} and Bayborodin, {Sergey I.} and Potter, {Ekaterina A.} and Taranov, {Oleg S.} and Omigov, {Vladimir V.} and Kochneva, {Galina V.} and Grazhdantseva, {Antonina A.} and Zavyalov, {Evgeniy L.} and Razumov, {Ivan A.} and Netesov, {Sergey V.} and Bogachev, {Sergey S.}",

year = "2019",

month = nov,

day = "1",

doi = "10.21873/anticanres.13815",

language = "English",

volume = "39",

pages = "6073--6086",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "11",

}

RIS

TY - JOUR

T1 - Oncolytic Effect of Adenoviruses Serotypes 5 and 6 Against U87 Glioblastoma Cancer Stem Cells

AU - Romanenko, Margarita V.

AU - Dolgova, Evgeniya V.

AU - Osipov, Ivan D.

AU - Ritter, Genrikh S.

AU - Sizova, Mariya S.

AU - Proskurina, Anastasia S.

AU - Efremov, Yaroslav R.

AU - Bayborodin, Sergey I.

AU - Potter, Ekaterina A.

AU - Taranov, Oleg S.

AU - Omigov, Vladimir V.

AU - Kochneva, Galina V.

AU - Grazhdantseva, Antonina A.

AU - Zavyalov, Evgeniy L.

AU - Razumov, Ivan A.

AU - Netesov, Sergey V.

AU - Bogachev, Sergey S.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - BACKGROUND/AIM: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. MATERIALS AND METHODS: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. RESULTS: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. CONCLUSION: Ad6 was shown to be a promising agent for treating glioblastomas.

AB - BACKGROUND/AIM: Oncolytic adenoviruses are promising therapeutic agents against both the bulk of tumor cells and cancer stem cells. The present study intended to test the oncolytic capability of adenovirus serotype 6 (Ad6), which has a lower seroprevalence and hepatotoxicity relatively to adenovirus 5 (Ad5), against the glioblastoma and its cancer stem cells. MATERIALS AND METHODS: Oncolytic efficacy of Ad6 was compared to widespread Ad5 both in vitro and in vivo, using the U87 and U251 human glioblastoma cell lines and subcutaneously transplanted U87 cells in SCID mice, respectively. RESULTS: Ad6 had a dose-dependent cytotoxicity toward glioblastoma cells in vitro and its intratumoral injections lead to a significant (p<0.05) decrease in volume of U87 xenografts, similarly to Ad5. Based on the innate capability of glioblastoma cancer stem cells to internalize a fluorescent-labeled double-stranded DNA probe, the spatial localization of these cells was estimated and it was shown that the number of cancer stem cells tended to decrease under adenovirus therapy as compared to the control group. CONCLUSION: Ad6 was shown to be a promising agent for treating glioblastomas.

KW - Adenovirus

KW - cancer stem cells

KW - DNA internalization

KW - TAMRA

KW - U87 cell line

KW - Cell Proliferation

KW - Humans

KW - Neoplastic Stem Cells/metabolism

KW - Adenoviruses, Human/classification

KW - Mice, SCID

KW - Glioblastoma/genetics

KW - Oncolytic Virotherapy

KW - Xenograft Model Antitumor Assays

KW - Animals

KW - Virus Replication

KW - Mice

KW - Tumor Cells, Cultured

KW - Apoptosis

KW - Cancer stem cells

KW - Аdenovirus

UR - http://www.scopus.com/inward/record.url?scp=85074717832&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13815

DO - 10.21873/anticanres.13815

M3 - Article

C2 - 31704835

AN - SCOPUS:85074717832

VL - 39

SP - 6073

EP - 6086

JO - Anticancer research

JF - Anticancer research

SN - 0250-7005

IS - 11

ER -

ID: 22335062